Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dZkbCfbwoceSwShRNutq

  ADVERTISEMENT  
November 9, 2012News for the transfusion medicine and cellular therapy community

  Top Story 
 
  • Blood stem cell trigger gene could increase transplant supply
    Canadian and Italian researchers said they have pinpointed what they call "a master control" gene that plays a role in switching on dormant blood stem cells. The findings could lead to methods that increase the amount of stem cells from cord blood available for transplantation. The study was reported in the journal Cell: Stem Cell. The Globe and Mail (Toronto) (tiered subscription model) (11/8) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
Quotient is on a roll with new FDA approvals & GPO contracts
More good news from Quotient! Not only do we have FDA-approved Reagent Red Blood Cells products, but also just approved Rare Antisera, including Anti-s and Anti-Wra. We also have new 3-yr agreements with Premier Inc. and the General Services Administration. Great products and value from the one manufacturer focused on manual testing. Contact us today.

  Science & Health 
  • Neurologists see signs of a more damaging West Nile virus
    Some cases of West Nile virus infection appear to be causing more damage to the brain than in previous outbreaks, indicating the virus may have mutated, two neurologists say. However, a CDC researcher says this year's infections do not appear to be causing a different kind of harm to the brain than in previous years. The Washington Post (11/8) LinkedInFacebookTwitterEmail this Story
  • Researchers fight multiple myeloma with data
    A collaboration between the Dana-Farber Cancer Center in Boston, the Mount Sinai School of Medicine in New York and analytics company GNS Healthcare will use GNS' Reverse Engineering and Forward Simulation supercomputer-based platform to look for new targets and therapies for multiple myeloma. "We're now in a position with these rich data sets to really pinpoint the most efficacious drug targets," said GNS CEO and founder Colin Hill. Xconomy (11/8) LinkedInFacebookTwitterEmail this Story
  • Cancer study to follow 300,000 people, assess blood samples
    The American Cancer Society has launched the Cancer Prevention Study-3, which will monitor 300,000 people in the U.S. who have not had cancer to improve understanding of factors that could lead to the disease. Participants will answer surveys, give blood samples and have their waists measured as part of the study. Blood samples will be stored as the study progresses and will be analyzed if participants are diagnosed. Star-News (Wilmington, N.C.) (11/8) LinkedInFacebookTwitterEmail this Story
  • Boy with cerebral palsy improves after cord blood treatment
    A boy from Maryland's Eastern Shore who was diagnosed with cerebral palsy is doing better following a transfusion of his own stored umbilical cord blood. He can walk and climb a short set of stairs. Doctors said there is a need to raise more awareness about the potential benefits of storing cord blood. WJZ-TV (Baltimore) (11/8) LinkedInFacebookTwitterEmail this Story
  • Study examines sexual behavior of young HIV patients
    Data from the Pediatric HIV/AIDS Cohort Study involving 330 patients who acquired HIV at birth found that 62% of those who were sexually active reported having unprotected sex. "Perinatally HIV-infected youth are like other adolescents across the country -- some are becoming sexually active, and they're practicing similar behaviors, including unprotected sex," a researcher said. The study was reported in the journal Clinical Infectious Diseases. Healio/Infectious Disease News (11/8) LinkedInFacebookTwitterEmail this Story
  Emerging Trends 
  • Scientists discover way to predict final protein shape
    Researchers from David Baker's laboratory at the University of Washington in Seattle created five proteins from scratch that are capable of folding into predictable structures. They tested and followed several intuitive rules to make the proteins, such as twisting the helices and other secondary structures formed by protein strands in one direction or another based on the length of the loops that linked them. "Rather than taking an already existing scaffold, now you can design a backbone to order for exactly the function you want to carry out," Baker said. Nature (11/7) LinkedInFacebookTwitterEmail this Story
  Industry News & Practice 
  • New blood test helps identify babesiosis in donated blood
    Initial findings from studies of Imugen's experimental blood tests to screen blood donors for babesiosis were presented at this year's AABB Annual Meeting. At the time of the meeting, about 20,000 blood donors had been tested for the disease using a new serologic test method and nucleic acid tests. The testing identified 69 units of blood that were potentially tainted with the disease and were removed from the blood supply. The studies are set to be completed early next year. InfectionControlToday.com (11/8) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
  • Group recommends changes to proposed device ID rule
    The proposal to create a unique device identifier system for medical technologies is the "most extensive and complex FDA regulation to be issued in recent memory," and the agency should work to "get it right the first time," said Janet Trunzo of the Advanced Medical Technology Association. The group recommends certain changes be made to the proposed rule, including extending to two years the time required for makers of Class III medical devices to adopt UDI. MedCityNews.com (11/8) LinkedInFacebookTwitterEmail this Story
  • King: Hamburg's continued role as FDA chief is good for drugmakers
    The pharmaceutical and biotech industry will benefit from the presumed continuation of Dr. Margaret Hamburg's role as commissioner of the FDA in President Barack Obama's second term, GlycoMimetics CEO and Biotechnology Industry Organization board member Rachel King said. "The consistency is positive," said King, who points to advances in the latest Prescription Drug User Fee Act, including the new "breakthrough therapies" designation, improved communication between drugmakers and the agency, and the expansion of accelerated approval. American City Business Journals/Washington, D.C. (11/7) LinkedInFacebookTwitterEmail this Story
  • HIT policy group requests comments on stage 3 MU proposals
    The Health IT Policy Committee is set to issue a request for public comments on its suggestions for the proposed meaningful use standard for stage 3 of the EHR incentive payment initiative. The group also seeks feedback on how to integrate consumer-reported information into clinical quality measures, which have been a component of MU specifications since the launch of the incentive program. Modern Healthcare (subscription required) (11/8) LinkedInFacebookTwitterEmail this Story
  Association News 
  • 2 new books available in the AABB Marketplace
    Two new books are available in the AABB Marketplace. The fourth edition of "Transfusion Reactions" is a prominent reference manual on noninfectious complications addressing clinical presentation, morbidity, differential diagnosis, mechanism of action, treatment and prevention for each type of complication. The book contains a new chapter addressing prevention strategies and the role of patient blood management. "Clinical Research: Understanding the Methodology Toolbox" is a compilation of evidence-based research articles that originally appeared as a feature, titled "Clinical Research Focus," in the journal "Transfusion." Written by recognized experts, the new book provides guidance on how to design, perform and publish the clinical research needed to fill some of the voids in scientific literature. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
West Coast Account ManagerMacopharma USAUS - Nationwide
VP Patient ServicesBlood Centers of the PacificUS - CA - San Francisco
Quality Source ConsultantBlood Systems, Inc.US - Nationwide
Quality SpecialistBlood Systems, Inc.US - NM - Albuquerque
Immunohematology Reference TechnologistLifeStreamUS - CA - San Bernardino
Help Desk SpecialistAABBUS - MD
Director, Operational Policies and Procedures (Corporate Donor Recruitment)Blood Systems, Inc.US - AZ - Scottsdale
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Staff AccountantAABBUS - MD
Marketing Manager, Cellular TherapiesAABBUS - MD
Director, LaboratorySan Diego Blood BankUS - CA - San Diego
Click here to view more job listings.

  SmartQuote 
A man who does not read good books has no advantage over the man who can’t read them."
--Mark Twain,
American writer


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information